EP3554506A4 - Bycyclic heteroaryl derivatives as cftr potentiators - Google Patents
Bycyclic heteroaryl derivatives as cftr potentiators Download PDFInfo
- Publication number
- EP3554506A4 EP3554506A4 EP17879832.8A EP17879832A EP3554506A4 EP 3554506 A4 EP3554506 A4 EP 3554506A4 EP 17879832 A EP17879832 A EP 17879832A EP 3554506 A4 EP3554506 A4 EP 3554506A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- heteroaryl derivatives
- cftr potentiators
- bycyclic
- bycyclic heteroaryl
- potentiators
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001072 heteroaryl group Chemical group 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662435253P | 2016-12-16 | 2016-12-16 | |
PCT/US2017/066317 WO2018112149A1 (en) | 2016-12-16 | 2017-12-14 | Bycyclic heteroaryl derivatives as cftr potentiators |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3554506A1 EP3554506A1 (en) | 2019-10-23 |
EP3554506A4 true EP3554506A4 (en) | 2020-06-10 |
EP3554506B1 EP3554506B1 (en) | 2021-04-28 |
Family
ID=62557188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17879832.8A Active EP3554506B1 (en) | 2016-12-16 | 2017-12-14 | Bycyclic heteroaryl derivatives as cftr potentiators |
Country Status (11)
Country | Link |
---|---|
US (4) | US10131670B2 (en) |
EP (1) | EP3554506B1 (en) |
JP (1) | JP7150721B2 (en) |
CN (1) | CN110300589B (en) |
AU (2) | AU2017378324B2 (en) |
BR (1) | BR112019012335A2 (en) |
CA (1) | CA3046968A1 (en) |
MX (1) | MX2019007135A (en) |
RU (1) | RU2753056C2 (en) |
SG (2) | SG10201911221RA (en) |
WO (1) | WO2018112149A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI735416B (en) | 2014-10-06 | 2021-08-11 | 美商維泰克斯製藥公司 | Modulators of cystic fibrosis transmembrane conductance regulator |
KR20180082556A (en) | 2015-11-25 | 2018-07-18 | 길리어드 아폴로, 엘엘씨 | Pyrazole ACC inhibitors and uses thereof |
SI3379933T1 (en) | 2015-11-25 | 2023-07-31 | Gilead Apollo, Llc | Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno(2,3-d)pyrimidine |
HUE053175T2 (en) | 2015-11-25 | 2021-06-28 | Gilead Apollo Llc | Ester acc inhibitors and uses thereof |
KR20180082557A (en) | 2015-11-25 | 2018-07-18 | 길리어드 아폴로, 엘엘씨 | Triazole ACC inhibitors and uses thereof |
CN109803962B (en) | 2016-09-30 | 2022-04-29 | 弗特克斯药品有限公司 | Modulators of cystic fibrosis transmembrane conductance regulator proteins, and pharmaceutical compositions |
MA54847A (en) | 2016-12-09 | 2021-12-08 | Vertex Pharma | CRYSTALLINE FORM OF AN N-(PYRAZOL-4-YL)SULFONYL-6-(PYRAZOL-1-YL)-2-(PYRROLIDIN-1-YL)PYRIDINE-3-CARBOXAMIDE FOR TREATING VUD |
EP3634402A1 (en) | 2017-06-08 | 2020-04-15 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2019018395A1 (en) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
ES2912657T3 (en) | 2017-08-02 | 2022-05-26 | Vertex Pharma | Processes for preparing pyrrolidine compounds |
AU2018351533B2 (en) | 2017-10-19 | 2023-02-02 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
KR20200097293A (en) | 2017-12-08 | 2020-08-18 | 버텍스 파마슈티칼스 인코포레이티드 | Method for producing a modulator of cystic fibrosis transmembrane conduction modulator |
TWI810243B (en) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | Pharmaceutical compositions for treating cystic fibrosis |
CN112004817B (en) | 2018-02-15 | 2023-06-23 | 弗特克斯药品有限公司 | Macrocyclic compounds as modulators of CFTR, pharmaceutical compositions thereof, their use and methods of preparation |
US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
AR118555A1 (en) * | 2019-04-03 | 2021-10-20 | Vertex Pharma | MODULATING AGENTS OF THE TRANSMEMBRANE CONDUCTANCE REGULATOR OF CYSTIC FIBROSIS |
KR20220019015A (en) * | 2019-06-10 | 2022-02-15 | 노파르티스 아게 | Pyridine and pyrazine derivatives for the treatment of CF, COPD, and bronchiectasis |
JP2022541178A (en) | 2019-07-15 | 2022-09-22 | ノバルティス アーゲー | (S)-3-amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide preparations |
CN114599657A (en) | 2019-08-14 | 2022-06-07 | 弗特克斯药品有限公司 | Crystalline forms of a CFTR modulator |
TW202120517A (en) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | Process of making cftr modulators |
TW202115092A (en) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | Modulators of cystic fibrosis transmembrane conductance regulator |
CA3188234A1 (en) | 2020-08-20 | 2022-02-24 | Jeffrey Axelrod | Methods for treating respiratory diseases characterized by mucus hypersecretion |
CN112876524B (en) * | 2021-01-26 | 2022-10-28 | 上海法默生物科技有限公司 | Preparation method of Reideciclovir intermediate |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004100868A2 (en) * | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
WO2007079164A2 (en) * | 2005-12-29 | 2007-07-12 | Abbott Laboratories | Protein kinase inhibitors |
EP3541390A1 (en) * | 2016-11-18 | 2019-09-25 | Cystic Fibrosis Foundation Therapeutics Inc. | Pyrrolopyrimidines as cftr potentiators |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10135815A1 (en) | 2001-07-23 | 2003-02-06 | Bayer Ag | Use of imidazo-triazinone derivative phosphodiesterase 5 inhibitors e.g. for treatment of cardiac insufficiency, psoriasis, diabetes, cancer, glaucoma, bladder disease, Parkinson's disease or pain |
TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
US7429596B2 (en) * | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
JP5249776B2 (en) | 2005-12-02 | 2013-07-31 | バイエル・ヘルスケア・エルエルシー | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyperproliferative diseases and diseases associated with angiogenesis |
PT2004654E (en) * | 2006-04-04 | 2013-08-27 | Univ California | Pyrazolopyrimidine derivatives for use as kinase antagonists |
BRPI0820342A2 (en) * | 2007-11-07 | 2015-05-26 | Foldrx Pharmaceuticals Inc | Protein Traffic Modulation |
SI2531187T1 (en) * | 2010-02-05 | 2016-01-29 | Adverio Pharma Gmbh | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS |
UY34484A (en) * | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | BENZOTIENILO-PIRROLOTRIAZINAS DISUSTITUIDAS AND ITS USES |
WO2015001491A1 (en) | 2013-07-02 | 2015-01-08 | Rhizen Pharmaceuticals Sa | Pi3k protein kinase inhibitors, particularly delta and/or gamma inhibitors |
-
2017
- 2017-12-14 BR BR112019012335-0A patent/BR112019012335A2/en active Search and Examination
- 2017-12-14 EP EP17879832.8A patent/EP3554506B1/en active Active
- 2017-12-14 SG SG10201911221RA patent/SG10201911221RA/en unknown
- 2017-12-14 JP JP2019531417A patent/JP7150721B2/en active Active
- 2017-12-14 CA CA3046968A patent/CA3046968A1/en active Pending
- 2017-12-14 AU AU2017378324A patent/AU2017378324B2/en active Active
- 2017-12-14 RU RU2019120990A patent/RU2753056C2/en active
- 2017-12-14 WO PCT/US2017/066317 patent/WO2018112149A1/en unknown
- 2017-12-14 MX MX2019007135A patent/MX2019007135A/en unknown
- 2017-12-14 US US15/841,902 patent/US10131670B2/en active Active
- 2017-12-14 CN CN201780086700.9A patent/CN110300589B/en active Active
- 2017-12-14 SG SG10201911076QA patent/SG10201911076QA/en unknown
-
2018
- 2018-09-17 US US16/132,894 patent/US10208053B2/en active Active
- 2018-09-17 US US16/132,960 patent/US10377762B2/en active Active
-
2019
- 2019-07-09 US US16/506,883 patent/US10766904B2/en active Active
-
2021
- 2021-12-02 AU AU2021277702A patent/AU2021277702B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004100868A2 (en) * | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
WO2007079164A2 (en) * | 2005-12-29 | 2007-07-12 | Abbott Laboratories | Protein kinase inhibitors |
EP3541390A1 (en) * | 2016-11-18 | 2019-09-25 | Cystic Fibrosis Foundation Therapeutics Inc. | Pyrrolopyrimidines as cftr potentiators |
Non-Patent Citations (2)
Title |
---|
S. M. ROWE ET AL: "Cystic Fibrosis Transmembrane Regulator Correctors and Potentiators", COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, vol. 3, no. 7, 1 July 2013 (2013-07-01), pages a009761 - a009761, XP055559276, DOI: 10.1101/cshperspect.a009761 * |
See also references of WO2018112149A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP3554506A1 (en) | 2019-10-23 |
WO2018112149A1 (en) | 2018-06-21 |
SG10201911221RA (en) | 2020-02-27 |
US20190016727A1 (en) | 2019-01-17 |
US10377762B2 (en) | 2019-08-13 |
CN110300589A (en) | 2019-10-01 |
CA3046968A1 (en) | 2018-06-21 |
RU2019120990A3 (en) | 2021-01-18 |
US10131670B2 (en) | 2018-11-20 |
BR112019012335A2 (en) | 2020-03-03 |
MX2019007135A (en) | 2019-11-18 |
AU2017378324A1 (en) | 2019-06-27 |
US20180170938A1 (en) | 2018-06-21 |
SG10201911076QA (en) | 2020-01-30 |
US10208053B2 (en) | 2019-02-19 |
EP3554506B1 (en) | 2021-04-28 |
CN110300589B (en) | 2023-03-10 |
JP2020502103A (en) | 2020-01-23 |
AU2017378324B2 (en) | 2021-09-02 |
US20190016728A1 (en) | 2019-01-17 |
RU2019120990A (en) | 2021-01-18 |
JP7150721B2 (en) | 2022-10-11 |
RU2753056C2 (en) | 2021-08-11 |
AU2021277702B2 (en) | 2023-11-30 |
US20190330219A1 (en) | 2019-10-31 |
US10766904B2 (en) | 2020-09-08 |
AU2021277702A1 (en) | 2021-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3554506A4 (en) | Bycyclic heteroaryl derivatives as cftr potentiators | |
EP3541390A4 (en) | Pyrrolopyrimidines as cftr potentiators | |
EP3615539A4 (en) | 2-amino-quinoline derivatives | |
EP3496717A4 (en) | 4-substituted aminoisoquinoline derivatives | |
EP3338458A4 (en) | Earphone | |
EP3438109A4 (en) | Heterocyclic compound | |
EP3564232A4 (en) | Bmp-signal-inhibiting compound | |
EP3498693A4 (en) | Heterocyclic compound | |
EP3215147A4 (en) | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods | |
EP3465449A4 (en) | Memory protocol | |
EP3297926A4 (en) | Carton with opening feature | |
EP3564216A4 (en) | Pyrimidine derivative | |
EP3438103A4 (en) | Griseofulvin compound | |
EP3533799A4 (en) | Compound | |
EP3525479A4 (en) | Headphone | |
EP3526215A4 (en) | N-acylethanolamide derivatives and uses thereof | |
EP3476510A4 (en) | Drill | |
EP3444239A4 (en) | Heterocyclic compound | |
EP3383401A4 (en) | Thieno-pyrimidine derivatives and uses thereof | |
EP3546462A4 (en) | Novel oxoisoquinoline derivative | |
EP3418276A4 (en) | Azole-substituted pyridine compound | |
EP3424905A4 (en) | Heterocyclic compound | |
EP3352758A4 (en) | Deuterated cftr potentiators | |
EP3408269A4 (en) | Viologen-based rotaxanes | |
EP3405455A4 (en) | 2-oxindole compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190716 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: THORARENSEN, ATLI Inventor name: MOUSSEAU, JAMES, JOHN Inventor name: STROHBACH, JOSEPH, WALTER Inventor name: EFREMOV, IVAN, VIKTOROVICH Inventor name: ZAPF, CHRISTOPH, WOLFGANG Inventor name: MATHIAS, JOHN, PAUL Inventor name: DENNY, RAJIAH, ALDRIN Inventor name: LIMBURG, DAVID, CHRISTOPHER |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CYSTIC FIBROSIS FOUNDATION |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602017037843 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0031519000 Ipc: C07D0487040000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200513 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/519 20060101ALI20200507BHEP Ipc: A61K 31/4162 20060101ALI20200507BHEP Ipc: C07D 487/04 20060101AFI20200507BHEP Ipc: A61P 11/00 20060101ALI20200507BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40015891 Country of ref document: HK |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20201117 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1386942 Country of ref document: AT Kind code of ref document: T Effective date: 20210515 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602017037843 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1386942 Country of ref document: AT Kind code of ref document: T Effective date: 20210428 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210728 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210830 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210728 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210729 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210828 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20210428 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602017037843 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20220131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210828 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20211231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211214 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211214 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211231 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211231 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20171214 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231108 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20231108 Year of fee payment: 7 Ref country code: DE Payment date: 20231108 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210428 |